Sir, Voriconazole is a broad-spectrum triazole used in the treatment of many fungal infections including those caused by Scedosporium spp. Along with significant side effects, voriconazole has a variable metabolism and multiple drug interactions, requiring regular monitoring. We present a case of disseminated Scedosporium apiospermum infection in a patient who was treated with voriconazole, but was unable to achieve therapeutic levels, with a resultant clinical relapse while on flucloxacillin for a Staphylococcus aureus bloodstream infection.
The patient's infection involved the skin, lungs and brain, and occurred against a background of recently commenced low-dose prednisolone for polymyalgia rheumatica. Skin biopsies isolated S. apiospermum, and the patient was started on voriconazole and terbinafine. Other medications included docusate with sennosides, magnesium and potassium supplements. After 8 days, the terbinafine was ceased due to liver derangement, which subsequently improved. Therapeutic voriconazole levels (1 -5.5 mg/L) were achieved, with clinical improvement of the skin lesions. On Day 33 of treatment, the patient developed an MSSA bloodstream infection and was started on 2 g of flucloxacillin intravenously four times a day. No other changes were made to the patient's medications. The subsequent voriconazole levels fell to ,1 mg/L and remained subtherapeutic despite intravenous or increasingly higher oral dosing, until the flucloxacillin was ceased (Figure 1 ). While the patient had subtherapeutic voriconazole levels, they developed new skin lesions that were confirmed as S. apiospermum on a repeat biopsy, and the patient was restarted on terbinafine.
The activity of voriconazole against Scedosporium is well described, and it is considered to be first-line treatment for S. apiospermum infection.
1,2 It inhibits fungal cytochrome P450, impairing the synthesis of ergosterol, but is also metabolized by hepatic cytochrome P450 enzymes CYP2C19, CYP3A4 and CYP2C9, with ,2% being excreted unchanged in the urine. Its bioavailability is estimated to be .90% in healthy adults. Monitoring of drug levels is recommended due to a low therapeutic index, a significant interindividual variation in the expression and function of CYP2C19 and CYP3A4, and the highly variable non-linear kinetics of voriconazole. 3 -5 Flucloxacillin, a semi-synthetic penicillin used for Grampositive infections including those caused by S. aureus, is not a substrate or an inhibitor of cytochrome P450 enzymes. However, at high and/or multiple doses, flucloxacillin activates the pregnane X receptor (PXR) nuclear hormone receptor, with the potential to induce the expression of both CYP3A4 and CYP2C8/9 in a genotype-dependent manner.
6,7 Levels of repaglinide (as a major substrate of CYP3A4 and used as a marker of PXR activity) reduce markedly following multiple doses of flucloxacillin. 6 Interaction with cyclosporine (which is predominantly metabolized by CYP3A4) has also been observed, with levels falling by up to 55% in renal transplant patients receiving intravenous flucloxacillin, resulting in transplant rejection. 8 The comparable antistaphylococcal penicillins dicloxacillin and nafcillin also activate PXR and increase CYP3A4 activity 9 and potentially have similar clinical implications.
We propose that flucloxacillin-mediated PXR activation was the cause of this patient's subtherapeutic voriconazole levels. To the best of our knowledge, this is the first documented interaction between these two medications. We recommend close surveillance when flucloxacillin (and potentially dicloxacillin and nafcillin) is used concurrently with voriconazole.
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Superficial mycotic skin infections represent the most frequent form of fungal infections with a prevalence of 20%-25% of the entire world population and are caused mainly by dermatophytes. 6 According to most publications and treatment guidelines, the drug of choice for treating these infections is terbinafine. 7 Furthermore, terbinafine is more cost-effective against dermatophytes compared with other antifungal agents. 8 Whether the lower
